The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 176, Issue 1, Pages 76-85
Publisher
Wiley
Online
2016-11-08
DOI
10.1111/bjh.14382
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy
- (2016) Ruben Mesa et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease
- (2016) Holly Geyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat polycythemia vera
- (2014) A. M. Vannucchi BLOOD
- Cytokine profiles in polycythemia vera and essential thrombocythemia patients: Clinical implications
- (2014) Emmanuel Pourcelot et al. EXPERIMENTAL HEMATOLOGY
- Aquagenic pruritus in polycythemia vera: Characteristics and influence on quality of life in 441 patients
- (2013) Fabian P. Siegel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
- (2013) G. Barosi et al. BLOOD
- Myeloproliferative neoplasms and thrombosis
- (2013) T. Barbui et al. BLOOD
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2013) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms
- (2013) Johanna Abelsson et al. LEUKEMIA & LYMPHOMA
- Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis
- (2012) Rakhee Vaidya et al. AMERICAN JOURNAL OF HEMATOLOGY
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera
- (2011) A. Alvarez-Larran et al. BLOOD
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms
- (2011) Peter Johansson et al. LEUKEMIA & LYMPHOMA
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
- (2010) T. Barbui et al. HAEMATOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More